A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

November 30, 2018

Study Completion Date

November 30, 2018

Conditions
Neuroendocrine TumorsLiver Metastases
Interventions
DRUG

177Lu-DOTA-TATE

"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.~Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."

Trial Locations (2)

413 45

Sahlgrenska University Hospital, Department of Oncology, Gothenburg

221 85

Department of Oncology, Lund University Hospital, Lund

All Listed Sponsors
lead

Lund University Hospital

OTHER

NCT01456078 - A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter